Ischemic Optic Neuropathy from Giant Cell Arteritis

Update item information
Identifier 20190318_nanos_hottopic1_01
Title Ischemic Optic Neuropathy from Giant Cell Arteritis
Creator Fiona Costello, MD, FRCP
Subject Ischemic Optic Neuropathy (ION); Giant Cell Arteritis (GCA); Corticosteroids; Steroid Sparing Therapies; Tocilizumab
Description Giant cell arteritis (GCA) is a challenging condition to manage. Patients presenting with ION warrant special consideration, because their vision loss is often irreversible. In general terms, the neuroophthalmic care of these patients is governed by several universal goals, namely: preserving or improving the visual status of the patient; protecting the patient from non-visual consequences of the diagnosis; and, ameliorating the inevitable effects of high-dose, long term corticosteroid therapy. Yet, for any given patient there are also challenges that are case specific. Clinicians caring for these individuals must consider the relative frailty of the patient, and anticipate what co-morbidities may be unveiled or exacerbated by treatment. Moreover, the severity of the patient's vision loss, and presence or absence of non-visual manifestations also impact management decisions.
Relation is Part of NANOS Annual Meeting 2019: Hot Topics: How Do I Treat?
Contributor Primary Fiona Costello, MD, FRCP
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date 2019-03
Format video/mp4
Source 2019 North American Neuro-Ophthalmology Society Annual Meeting
Rights Management Copyright 2019. For further information regarding the rights to this collection, please visit:
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Collection Neuro-ophthalmology Virtual Education Library: NOVEL
Language eng
ARK ark:/87278/s6809hz5
Setname ehsl_novel_nam
Date Created 2019-05-10
Date Modified 2021-05-06
ID 1426194
Reference URL
Back to Search Results